NCT07137585

A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity

Effects of RO7204239 on Insulin Sensitivity, Muscle Composition and Function in Participants Living With Type 2 Diabetes Mellitus and Overweight or Obesity: A Double-blind, Randomized, Placebo-controlled Study

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to assess the effect of RO7204239 on insulin sensitivity versus placebo in participants with T2DM and obesity or overweight.

Conditions

• Type 2 Diabetes Mellitus
• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Placebo	RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.
DRUG	RO7204239	RO7204239 will be administered as per the schedule specified in the treatment arm.

Timeline

• Start date: 2025-09-30
• Primary completion: 2026-09-13
• Completion: 2027-02-28
• First posted: 2025-08-22
• Last updated: 2026-04-13

Locations

1 site across 1 country: Germany